Preclinical data presented at Alzheimer’s Association International Conference (AAIC) 2020
Dr. Anders Sandberg, Chief Scientific Officer, presented data on the Company's substances. The poster provides an overview of the Company's research strategy and data demonstrating that the monoclonal antibody ALZ-201, which specifically targets Aβ42 oligomers, is able to neutralize the neurotoxic effect as effectively as an antibody that binds to all forms of Aβ. This has been studied in two different preclinical Alzheimer's disease models based on human brain tissue.
The findings demonstrate that oligomers are present in low levels in the brain of patients, and that targeting these with high specificity is likely required to achieve therapeutic efficacy. The data support the continued development of the Company’s lead candidate, ALZ-101. The data were presented at the Alzheimer’s Association International Conference 2020 (AAIC) on July 29.